Establishing the Leader in Cannabinoid Biosynthetic Production
<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Corporate Highlights</td>
<td>3 – 5</td>
</tr>
<tr>
<td>2. Market Opportunity</td>
<td>6 – 10</td>
</tr>
<tr>
<td>3. Willow Advantages</td>
<td>11 - 15</td>
</tr>
<tr>
<td>4. Leadership / Technical Team &amp; Board of Directors</td>
<td>16 – 19</td>
</tr>
<tr>
<td>5. Thebaine Case Study</td>
<td>20 – 22</td>
</tr>
<tr>
<td>6. Capital Structure &amp; 24-Month Budget</td>
<td>23 – 24</td>
</tr>
<tr>
<td>7. Summary</td>
<td>25</td>
</tr>
</tbody>
</table>
EXECUTIVE SUMMARY & CORPORATE HIGHLIGHTS
INVESTMENT HIGHLIGHTS

MASSIVE UNTAPPED MARKET
Accelerating demand for cannabinoids and sky-high purification costs create need for advanced, cheaper manufacturing

UNPARALLELED HUMAN CAPITAL
World-leading discovery biologists guide multidisciplinary team, business experts who have ‘been there’ and ‘done that’

DISTINCT VALUE PROPOSITION
Biosynthesis of cannabinoids provides the utmost product quality at scale for the lowest cost

PROVEN ABILITY TO EXECUTE
Similar research and development program recently completed in opioids
ONE-OF-A-KIND OPPORTUNITY

- Go-public transaction of Willow Bioscience through the recapitalization of a public company listed on the CSE or TSXV and a non-brokered private placement raising up to $20 million

- Positioned to become the industry leader and capture key intellectual property around the most cost-effective methods to produce cannabinoids

- Operational capabilities span the entire product development pathway with an integrated team in Canada & the US that has full end-to-end capabilities to underpin achievement at all stages of development cycle

Cannabis Research
Vancouver & Calgary

Discovery & Synthetic Biology
Calgary & San Francisco

Process Scale-Up
Calgary

Commercialization
Calgary & Boston

- IP platform + scientific team = commercialized cannabinoid production targeted ~24 months

Biosynthetic cannabinoid production allows for a distinct and repeatable cost advantage over current plant-based extraction
MARKET OPPORTUNITY
Background

- Epidiolex, a CBD-based oral solution, was approved by US FDA on June 25, 2018 to treat seizures associated with two forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients 2+ years of age(1)

Significance

- First FDA-approved drug comprised of an active ingredient derived from marijuana
- Current US demand for API grade CBD is ~5,000 kg/year for Dravet and Lennox-Gastaut(2)

Near Term Potential Market for API Grade Products

- Tuberous Sclerosis (new drug application (NDA) ~2019) represents ~5,000 kg/year additional demand(2)
  - Target market for all pharmaco-resistant childhood epilepsies (~169,000 children) expected to exceed 37,000 kg/year(2)
- Sativex (CBD + THC) indicated for MS Spasticity (NDA 2019/2020)(3)
- CBDV, CBD and THC will be in Phase II or III clinical trials for GBM, Autism and NHEI in next 2-3 years(3)
- Future global demand for cannabinoid APIs could be hundreds of tonnes annually(4)

(1) https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm611046.htm
(2) GW Pharmaceuticals plc Investor Presentation (September 2018) and Willow management estimates
(3) GW Pharmaceuticals plc Investor Presentation (September 2018)
(4) Willow management estimates
CBD API MARKET:
Willow Initial Market Focus

- Demand for pharmaceutical CBD to treat pharmaco-resistant childhood epilepsy could reach a single drug/single purpose annual market of US$550 million in the US alone\(^{(1)}\)
- ~300 CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as PTSD, epilepsy, Parkinson's disease, chronic pain, schizophrenia and others\(^{(2)}\)
- Applications for pharma-grade cannabinoids will continue to expand

### CBD API Market Price, Cost & Potential Market Capture\(^{(3)}\)

<table>
<thead>
<tr>
<th>CBD API Market Size</th>
<th>5,000 kg/yr</th>
<th>10,000 kg/yr</th>
<th>37,000 kg/yr</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Market Price</strong> (US$/kg)</td>
<td>$15,000(^{(4)})</td>
<td>$75mm</td>
<td>$150mm</td>
</tr>
<tr>
<td><strong>Plant-Based Extraction</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost (US$/kg)</td>
<td>$15,000(^{(4)})</td>
<td>$75mm</td>
<td>$150mm</td>
</tr>
<tr>
<td>Gross Margin (US$)</td>
<td>$0</td>
<td>$0mm</td>
<td>$0mm</td>
</tr>
<tr>
<td><strong>Biosynthetic Extraction</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost (US$/kg)</td>
<td>$1,000(^{(5)})</td>
<td>$5mm</td>
<td>$10mm</td>
</tr>
<tr>
<td>Gross Margin (US$)</td>
<td>$14,000</td>
<td>$70mm</td>
<td>$140mm</td>
</tr>
</tbody>
</table>

### Willow Potential Revenue by Market Penetration (%)

- 25%
- 50%
- 75%

---

\(^{(1)}\) GW Pharmaceuticals plc Investor Presentation (September 2018) and Willow management estimates
\(^{(2)}\) Willow management estimates
\(^{(3)}\) All dollar figures are in USD unless otherwise indicated
\(^{(4)}\) Public industry data, competitor disclosure and Willow competitor analysis
\(^{(5)}\) Management estimates
IMMENSE MARKET OPPORTUNITY: CONSUMER USE

- Extracts made up 31% of California’s cannabis as of Dec. 2017\(^1\)
  - California’s total cannabis market is expected to hit US$31.4 billion by 2021\(^1\)
- Canadian extract market is projected to exceed C$2.5 billion by 2020\(^1\)
- Synthetic biology production systems enable Willow to produce pure cannabinoid fine chemicals for the consumer use markets at a significant discount relative to plant-based extraction methods
- Biosynthetic manufacturing up to **5 times more cost effective** in consumer use market and yields product with higher purity and consistency

\(^1\) https://investingnews.com/innspired/north-america-market-for-cannabis-extracts/
CBD CONSUMER PRODUCT MARKET

• CBD is non-psychoactive, nonaddictive and has therapeutic benefits\(^{(1)}\)

• Health and wellness applications for CBD in consumer products are far-reaching

• Massive market opportunity to develop cosmetics, anti-aging skin creams, arthritic topical creams, pet treats, athletic recovery elixirs, pain relievers and other products

• CBD market projected to grow 700% by 2020 to US$2.1 billion with growth forecasts as high as US$3 billion by 2021 and the potential to exceed US$200 billion in the US\(^{(2)(3)(4)}\)

• Canadian lawmakers may allow natural health products (NHP) to contain cannabis and cannabinoids, including CBD

“We will be in a ready to go position (in the lucrative cannabis drinks market) and one of the first on the playing field as the market opens up”

- Mark Hunter, CEO Molson Coors\(^{(5)}\)

---

\(^{(1)}\) According to World Health Organization. Cannabis Newswire: https://goo.gl/Gcixu2


\(^{(3)}\) MarketNewsUpdates.com: https://goo.gl/nwX8UW

\(^{(4)}\) Provided that hemp is re-categorized as a legal crop. USA Today, Greenwave Advisors: https://goo.gl/Q1tsdT

\(^{(5)}\) BNN Bloomberg, Oct. 31, 2018: https://goo.gl/DU9XyN
WILLOW ADVANTAGES
THE WILLOW DIFFERENCE

Creating the only fully-integrated synthetic biology solution, from gene discovery to cannabinoid commercialization

UNPARALLELED HUMAN CAPITAL
Rare combination of world-leading discovery biologists and cannabis geneticists who have done this before in opioids

EXPEDITE “DESIGN-BUILD” CYCLE
Enhancing production yield through gene mutation-targeted evolution

ANTICIPATE INDUSTRY NEEDS
Understanding the market’s specific challenges, e.g. novel cannabinoid formulations, rare cannabinoids, solubility of cannabinoid products
## Willow Provides the Only True, Fully-Integrated Solution

<table>
<thead>
<tr>
<th>Feature</th>
<th>Others</th>
<th>Willow</th>
</tr>
</thead>
<tbody>
<tr>
<td>World-leading human capital enabling novel component discovery and rational design</td>
<td>x</td>
<td>✓</td>
</tr>
<tr>
<td>Novel genomics, transcriptomics and proteomic tools</td>
<td>x</td>
<td>✓</td>
</tr>
<tr>
<td>Proven best in class IP development and protection</td>
<td>x</td>
<td>✓</td>
</tr>
<tr>
<td>High throughput targeted evolution</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Fermentation production scale-up</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Commercialization of pharmaceutical-grade product</td>
<td>x</td>
<td>✓</td>
</tr>
</tbody>
</table>

Source: Public industry data; competitor disclosure and Willow competitor analysis
FULL END-TO-END CAPABILITIES

Stage 1
- T = 0
- 3-6 months
  - Idea Generation & Discovery Biology
    - Rebuild cannabis genome
    - Generate essential molecular biological tools
    - Establish base IP portfolio

Stage 2
- 6-12 months
  - High Throughput Mutagenesis & Strain Analytics
    - Mutating pathway genes through millions of experiments
    - Improved gene variants and integration sites results in production yield increases >10,000 fold

Stage 3
- 24 months
  - Fermentation Scale-Up
    - Cannabinoid yields of >2g/litre
    - Secure commercial scale fermentation

Stage 4
- T = 24 months
- 24 months
  - Commercialization of cannabinoids
    - Secure distribution agreement

The only fully-integrated synthetic biology solution, from gene discovery to cannabinoid commercialization

<table>
<thead>
<tr>
<th>Stage</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 1</td>
<td>30% complete</td>
</tr>
<tr>
<td>Stage 2</td>
<td>10% complete</td>
</tr>
<tr>
<td>Stage 3</td>
<td>&lt;5% complete</td>
</tr>
<tr>
<td>Stage 4</td>
<td>&lt;5% complete</td>
</tr>
</tbody>
</table>
DEVELOPMENT STRATEGY WILL ENABLE COMMERCIAL PRODUCTION OF MULTIPLE TARGETS

Cannabinoid Precursors

Hexanoic Acid

Olivetolic Acid

CBGA

Butyric Acid

Divarinic Acid

CBGVA

Key Cannabinoid Intermediates

Naturally Occurring

THCA

CBD (1st target)

CBCA

To be developed

THCVA

CBDVA

CBCVA

Decarboxylation

THC

CBD

CBC

THCV

CBDV

CBCV

Commercial titer target of 3-5 g/L necessary for COGS targets is a realistic objective and will be the key optimization driver
LEADERSHIP, TECHNICAL & BOARD
• Extensive senior leadership experience
• CEO, CFO & Vice President of multiple public and private biotech companies
• Holds more than 20 issued or pending patents
• Member of the Board of Directors of BioAlberta
• Ph.D. in Biochemistry & Molecular Biology from the University of Calgary

• Experienced executive having co-founded four start-up companies in the past 15 years
• Instrumental in seven public and private start-up companies in the energy industry over the past 20 years
• Raised over $1 billion in equity and debt financings at various stages of corporate development
• Successful transactions totalling over $4 billion on sale
• Extensive intellectual property and patent prosecution background in the energy technology sector

• Professor of Plant Biochemistry in the Department of Biological Sciences at the University of Calgary since 1995
• Canada Research Chair in Plant Metabolic Processes Biotechnology
• Received the C.D. Nelson Award from the Canadian Society of Plant Physiologists as the outstanding young plant biologist in Canada
• Published over 130 research papers and scholarly articles in high-impact journals such as Nature Chemical Biology, Plant Cell, Plant Journal and the Journal of Biological Chemistry
• Ph.D. from the University of Toronto in 1991 and conducted postdoctoral research at the University of Kentucky and the Université de Montréal

• CA and CPA (Illinois) with 18+ years’ experience in the international oil and gas industry
• VP Finance & CFO of Suroco Energy Inc., a publicly-listed company based in Canada with operations in Colombia
• Roles with PwC in Calgary, Alberta and Havana, Cuba
• Served in positions of increasing importance at Sherritt Oil & Gas, including Finance Manager & Controller
• VP Finance & CFO of Milagro Energy and Controller of NAL Resources
On the committed morphine pathway in the opium poppy (i.e. from reticuline to morphine), the Willow team, headed by Peter Facchini, was the first to discover 5 of the 9 genes
### BOARD OF DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Experience/Qualifications</th>
</tr>
</thead>
</table>
| Peter Seufer-Wasserthal, PhD | Independent Director | • >25 years of experience in the technology and biotechnology sector  
• Currently Chief Commercial Officer of Origenis GmbH  
• Previously VP, Business Development for Intrexon Corporation, responsible for business development in Europe and Asia for four years  
• Received a Ph.D. (Technical University of Graz) |
| Donald Archibald      | Independent Director | • Independent businessman with significant senior executive and board experience for numerous public and private companies  
• Previous director and audit committee member of publicly-traded Spartan Energy Corp. and Spartan Oil Corp.  
• Previously President of Cypress Energy Corp., Chairman & CEO of Cyries Energy Inc. and President & CEO of Cequel Energy Inc.  
• Holds a B.Comm (University of Alberta) and MBA (University of Western Ontario) |
| Fotis Kalantzis, PhD  | Independent Director | • >25 years experience in oil and gas exploration and development  
• Co-founder and senior executive of several public companies including Spartan Energy Corp., Spartan Oil Corp. and Spartan Exploration Ltd.  
• Holds an M.Sc from the University of Saskatchewan and a PhD from the University of Alberta  
• Published and presented numerous papers in international journals and conferences |
| Sadiq Lalani          | Independent Director | • >25 years’ experience as Chief Financial Officer of publicly-listed issuers, including current Vice President & CFO at Kelt Exploration Ltd.  
• C-Suite Energy Executive Awards CFO of the Year |
| Joseph Tucker, PhD    | Executive Chair                     | • See Leadership |
| Trevor Peters         | CEO & Director                      | • See Leadership |
| Sony Gill             | Corporate Secretary                 | • Partner at McCarthy Tétrault LLP, a national law firm  
• Extensive experience in all aspects of company creation, growth, restructuring and value maximization; skilled in negotiating, structuring and consummation of numerous corporate finance, securities and M&A transactions  
• Serves on the board and acts as corporate secretary to numerous public and private companies |
CASE STUDY
THEBAINE CASE STUDY:
First to Biosynthesize Thebaine in Yeast at Commercial Levels

- Willow team retained to scale-up yeast-based thebaine API production to commercially viable levels
- Using discovery biology, successfully increased thebaine API yields to commercially viable levels
- **Result:** Production yield increased by more than 10,000\(^{(1)}\) times and thebaine producing strain now undergoing process scale up for commercial manufacture

**Willow has a demonstrated and proven ability to biosynthesize commercially**

**Biosynthesis yields highest-grade product for industrial and pharmaceutical needs**

**Biosynthesis provides distinct value proposition to pharmaceuticals: higher yields, lower costs, higher purity**

---

\(^{(1)}\) Epimeron / Intrexon scale-up results

Strictly Private & Confidential
OPIOID PORTFOLIO

• Opioid portfolio
  • 14 patents that cover manufacture of
    • Thebaine
    • Hydrocodone, hydromorphone, oxycodone (semi-synthetics)
    • Naltrexone, naloxone, buprenorphine (semi-synthetics)

• Partner-funded project with Intrexon is complete: thebaine production brought up to commercial levels

• 7% royalty on thebaine production with Intrexon
  • Initial royalty revenue expected to start in the low to mid-single digit millions

• Globally, thebaine market is US$500 million

• Globally, semi-synthetic opioid markets are approximately US$15 billion
  • Early scaleup research underway for several semi-synthetics
CAPITAL STRUCTURE & 24-MONTH BUDGET
### Capital Structure (C$MM)

<table>
<thead>
<tr>
<th>Description</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Willow Equity Value(^{(1)})</td>
<td>$30.0</td>
</tr>
<tr>
<td>ShellCo Equity Value</td>
<td>$1.3</td>
</tr>
<tr>
<td>Financing Equity Value(^{(2)})</td>
<td>$15.0</td>
</tr>
</tbody>
</table>

**Market Capitalization** $46.3

<table>
<thead>
<tr>
<th>Description</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Willow Working Capital</td>
<td>$0.9</td>
</tr>
<tr>
<td>ShellCo Working Capital</td>
<td>$0.0</td>
</tr>
<tr>
<td>Financing Proceeds</td>
<td>$14.7</td>
</tr>
</tbody>
</table>

**Enterprise Value** $30.7

\(^{(1)}\) Based on 122.2 million Willow shares outstanding at a price $0.25 per share

\(^{(2)}\) The issue price for all subscribers shall be the same, however Management and Board shall receive 1.0 common share and 1.0 warrant exercisable at a 50% premium to the issue price and shall be subject to the following vesting conditions:

1. 1/3 upon 20 day VWAP exceeding 50% of issue price
2. 1/3 upon 20 day VWAP exceeding 100% of issue price
3. 1/3 upon 20 day VWAP exceeding 150% of issue price

In addition, in the event the 20-day VWAP exceeds 300% of the issue price, the warrants shall be exercisable for 1.5 common shares, provided that the shares are either (i) sold for cash, (ii) acquired for securities of a company listed on the TSX or (iii) the shares are listed on the TSX

### Capital & Operating Budget (C$MM)

<table>
<thead>
<tr>
<th>Description</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research &amp; Scale-Up</td>
<td></td>
</tr>
<tr>
<td>Capex</td>
<td>$5.0</td>
</tr>
<tr>
<td>Opex</td>
<td>$7.0</td>
</tr>
<tr>
<td>G&amp;A</td>
<td>$3.6</td>
</tr>
</tbody>
</table>

**Total 24 Month Corporate Budget** $15.6
THE WILLOW OPPORTUNITY

• Yeast fermentation cannabinoid production offers significant advantages over plant-based extraction:
  • Controlled manufacturing environment facilitates scale up, purity, security of product supply and is pesticide-free
  • Substantially more cost-effective
  • Rare cannabinoid production requires same cost inputs as CBD, opening up new consumer base and pharmaceutical markets

• Willow has proven ability to commercialize fermentation-based production
  • Discovery biology to identify important genes in desired metabolic pathways
  • High-throughput targeted evolution and screening technology to generate higher yields
  • Relationships with leading contract development and manufacturing organizations (CDMOs)

• Discovery biology expertise is Willow’s differentiating advantage in the emerging cannabis patent landscape

• Willow’s previous success securing intellectual property positions the company to protect and commercialize discoveries
  • Three of the most important genes in the committed morphine pathway in the opium poppy have been patented by Willow
This presentation does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein. The sole purpose of this presentation, in paper or electronic form, is strictly for information purposes. Neither BioCan Technologies Inc. ("BioCan" or the "Company") nor any of its current or proposed directors, officers, owners, managers, partners, consultants, employees, affiliates or representatives, make any warranty or representation, whether express or implied, or assume any legal liability or responsibility for any action taken in reliance upon this presentation, or for the accuracy, completeness, or usefulness of any information disclosed, including any pro-forma financial statements included in this presentation.

**Forward Looking Statements.** Certain information included in this presentation constitutes forward-looking information under applicable securities legislation. Forward-looking information typically contains statements with words such as “will”, “anticipate”, “believe”, “expect”, “plan”, “intend”, “estimate”, “propose” or similar words suggesting future outcomes or statements regarding an outlook. Forward-looking information in this presentation includes, but is not limited to, statements relating to: the proposed business combination of BioCan to create Willow Bioscience Ltd. (the “Transaction”); the proposed private placement financing to be completed by BioCan (the “Financing”) and the use of proceeds from the Financing; the expected composition of the management team and board of directors of the Company; the Company’s business, strategies, expectations, planned operations or future actions, including research and development programs and collaborations and partnerships; the performance of the Company’s business and operations; the competitive conditions of the industry in which the Company operates and the competitive advantages of the Company; and the Company’s future product offerings, including analytical testing, genetics, pest and disease management and cannabinoid production and the timing thereof.

The forward-looking statements contained in this presentation are based on certain key expectations and assumptions made by the Company, including expectations and assumptions concerning: BioCan, the Transaction, the Financing, the negotiation of the Financing on satisfactory terms, the timely receipt of all required securityholder, Court, stock exchange and regulatory approvals, the satisfaction of other closing conditions in accordance with the terms of the agreements in respect of the Transaction and the Financing, the future operations of, and transactions completed by, the Company; the availability of sufficient capital; the availability of and access to qualified personnel; the Company’s ability to develop and protect intellectual property; the expected growth in the cannabis market; the medical and therapeutic benefits, viability, safety, efficacy, dosing and social acceptance of cannabis; the securities markets and the general economy; federal and provincial regulations pertaining to the legalization of cannabis for adult-use in Canada and the Company’s intentions to participate in such market; the legalization of the use of cannabis for medical and/or adult use in jurisdictions outside of Canada; and applicable laws not changing in a manner that is unfavorable to the Company.
The Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These risks and uncertainties, include, but are not limited to, the results of the due diligence review on BioCan by the other party are less than satisfactory, the failure to complete the Financing on satisfactory terms or the parties are unable to obtain the required stock exchange and shareholder approvals, risks associated with the cannabis industry in general; actions and initiatives of federal and provincial governments and changes to government policies and the execution and impact of these actions, initiatives and policies; import/export and research restrictions for cannabinoid-based operations; the size of the medical-use and adult-use cannabis market; and competition from other industry participants.

Readers are cautioned that the assumptions used in the preparation of forward-looking information, although considered reasonable at the time of preparation, may prove to be imprecise. The Company's actual results, performance or achievement could differ materially from those expressed in, or implied by, these forward-looking statements and accordingly there can be no assurance that such expectations will be realized and/or what benefits the Company will derive therefrom. The forward-looking information contained in this presentation is made as of the date hereof and the Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless required by applicable securities laws. The forward looking information contained in this presentation is expressly qualified by this cautionary statement. Certain information contained herein has been obtained from published sources prepared by independent industry analysts and third-party sources (including industry publications, surveys and forecasts). While such information is believed to be reliable for the purpose used herein, none of the directors, officers, owners, managers, partners, consultants, shareholders, employees, affiliates or representatives assumes any responsibility for the accuracy of such information. None of the sources cited in this presentation have consented to the inclusion of any data from their reports, nor has the Company sought their consent.

**FOFI Disclosure.** This presentation contains future-oriented financial information and financial outlook information (collectively, “FOFI”) about the Company's prospective capital structure, enterprise value, EBITDA, revenue, expenses, profit and components thereof, all of which are subject to the same assumptions, risk factors, limitations and qualifications as set forth in the above paragraphs. FOFI contained in this presentation was made as of the date of this presentation and was provided for the purpose of providing further information about the Company’s anticipated future business operations. The Company disclaims any intention or obligation to update or revise any FOFI contained in this presentation, whether as a result of new information, future events or otherwise, unless required pursuant to applicable law. Readers are cautioned that the FOFI contained in this presentation should not be used for purposes other than for which it is disclosed herein.

**U.S. Registration.** This presentation is not an offer of the securities for sale in the United States. The securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.
Purchaser Rights of Action

Securities legislation in certain of the Canadian provinces provides certain purchasers of securities pursuant to an offering memorandum (such as this presentation) with a remedy for damages or rescission, or both, in addition to any other rights they may have at law, where the offering memorandum and any amendment thereto contains a "misrepresentation", as defined in the applicable securities legislation. Purchasers should refer to the applicable securities legislation for the complete text of these rights or consult with a legal adviser. A "misrepresentation" is generally defined under applicable provincial securities laws to mean an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make any statement not misleading in light of the circumstances in which it was made. These remedies, or notice with respect to these remedies, must be exercised or delivered, as the case may be, by the purchaser within the time limits prescribed by applicable securities legislation and are subject to limitations and defences under applicable securities legislation.

The following is a summary of the relevant rights of action for damages or rescission, or both, available to certain purchasers resident in certain of the provinces of Canada.

**British Columbia, Alberta and Québec**

Notwithstanding that the Securities Act (British Columbia), the Securities Act (Alberta) and the Securities Act (Québec), and the rules, regulations and instruments thereunder, do not provide, or require BioCan to provide, to purchasers resident in these jurisdictions any rights of action in circumstances where this presentation or an amendment thereto contains a misrepresentation, BioCan hereby grants to such purchasers contractual rights of action that are equivalent to the statutory rights of action set forth above with respect to purchasers resident in Ontario.

**Manitoba, Northwest Territories, Yukon and Nunavut**

The Securities Act (Manitoba), the Securities Act (Northwest Territories), the Securities Act (Yukon) and the Securities Act (Nunavut) each provide a statutory right of action for damages or rescission to purchasers resident in Manitoba, the Northwest Territories, Yukon and Nunavut, respectively, in circumstances where an offering memorandum (such as this presentation), or an amendment thereto, contains a misrepresentation.

**New Brunswick**

The right of action for damages or rescission described herein is conferred by Section 150 of the Securities Act (New Brunswick) (the "New Brunswick Act"). Section 2.1 of New Brunswick Securities Commission Rule 45-802 Prospectus and Registration Exemptions provides that the statutory rights of action for damages or rescission referred to in Section 150 of the New Brunswick Act apply to information relating to an offering memorandum (such as this presentation) that is provided to a purchaser of securities in connection with a distribution made in reliance on the "accredited investor" prospectus exemption in Section 2.3 of National Instrument 45-106. The New Brunswick Act provides, in relevant part, that where an offering memorandum (such as this presentation) contains a misrepresentation, as defined in the New Brunswick Act, a purchaser who purchases securities offered by the offering memorandum shall be deemed to have relied on the misrepresentation if it was a misrepresentation at the time of purchase and: (a) the purchaser has a right of action for damages against the issuer and any selling security holder(s) on whose behalf the distribution is made; or (b) where the purchaser purchased the securities from a person referred to in paragraph (a), the purchaser may elect to exercise a right of rescission against the person, in which case the purchaser shall have no right of action for damages against the person. This statutory right of action is available to New Brunswick purchasers whether or not such purchasers relied on the misrepresentation. However, there are various defences available to the issuer and the selling security holder(s). These rights are in addition to, and without derogation from, any other rights or remedies available at law to a New Brunswick purchaser. The foregoing is a summary of the rights available to a New Brunswick purchaser. New Brunswick purchasers should refer to the complete text of the relevant statutory provisions.
Ontario

The Securities Act (Ontario) provides that every purchaser of securities offered pursuant to an offering memorandum (such as this presentation) shall have a statutory right of action for damages or rescission against BioCan in the event that this presentation contains a misrepresentation. A purchaser who purchases securities has, without regard to whether the purchaser relied upon the misrepresentation, a right of action for damages or, alternatively, while still the owner of the securities, for rescission against BioCan, provided that if the purchaser exercises its right of rescission, it shall cease to have a right of action for damages as against BioCan; BioCan will not be liable for all or any portion of damages that it proves do not represent the depreciation in value of the securities as a result of the misrepresentation relied upon; and in no case shall the amount recoverable exceed the price at which the securities were offered. The Securities Act (Ontario) also provides that no action can be commenced to enforce these rights more than 180 days after the date of the transaction that gave rise to the cause of action in the case of rescission; or in a damages claim, the earlier of 180 days after the date that the purchaser first had knowledge of the facts giving rise to the cause of action or three years after the date of the transaction that gave rise to the cause of action. These rights are in addition to, and without derogation from, any other rights or remedies available at law to an Ontario purchaser. The foregoing is a summary of the rights available to an Ontario purchaser. Ontario purchasers should refer to the complete text of the relevant statutory provisions.

Saskatchewan

In the event that an offering memorandum, together with any amendments thereto, contains a misrepresentation, a purchaser resident in or otherwise subject to the laws of Saskatchewan to whom an offering memorandum has been sent or delivered and who purchases securities of the issuer covered by such offering memorandum shall be deemed to have relied on the misrepresentation if it was a misrepresentation at the time of purchase, and such purchaser has, in addition to any other right that they may have at law, a right of action for damages against the issuer and a selling security holder on whose behalf the distribution is made; every promoter and director of the issuer, or the selling security holder, as the case may be, at the time the offering memorandum or any amendment thereto is sent or delivered to a purchaser, and every person who, or company that, sells securities on behalf of the issuer or the selling security holder under such offering memorandum or any amendment thereto. The purchaser may elect to exercise a right of rescission against the issuer, in which case the purchaser will have no right of action for damages against the issuer, but may retain the right to claim damages against the other parties described above. However, there are various defences available to the persons or companies that the purchaser has a right to sue. In particular, in an action for damages, they have a defence if the purchaser knew of the misrepresentation when the purchaser purchased the securities of the issuer. Saskatchewan securities legislation provides a purchaser with the right to void the purchase agreement and to recover all money and other consideration paid by the purchaser for the securities if the securities are purchased from a vendor who is trading in Saskatchewan in contravention of Saskatchewan securities legislation. Saskatchewan securities legislation also provides a right of action for rescission or damages to a purchaser of securities to whom an offering memorandum or any amendment to it was not sent or delivered prior to or at the same time as the purchaser enters into an agreement to purchase the securities. If the purchaser intends to rely on the rights described above, the purchaser must do so within strict time limitations. The purchaser must commence an action to cancel the agreement within 180 days from the date of the transaction that gave rise to the cause of action. The purchaser must commence an action for damages within the earlier of one year after the purchaser first had knowledge of the facts giving rise to the cause of action and six years after the date of the transaction that gave rise to the cause of action. Saskatchewan securities legislation also provides a purchaser who has received an amended offering memorandum delivered in accordance with subsection 80.1(3) of The Securities Act, 1988 (Saskatchewan) with a right to withdraw from the agreement to purchase the securities by delivering a notice to the person who or company that is selling the securities, indicating the purchaser’s intention not to be bound by the purchase agreement, provided such notice is delivered by the purchaser within two business days of receiving the amended offering memorandum. These rights are in addition to, and without derogation from, any other rights or remedies available at law to a Saskatchewan purchaser. The Securities Act, 1988 (Saskatchewan) provides a number of limitations and defences in respect of such rights. The foregoing is a summary of the rights available to a Saskatchewan purchaser. Saskatchewan purchasers should refer to the complete text of the relevant statutory provisions.
PURCHASER RIGHTS OF ACTION (continued)

Prince Edward Island
The right of action for damages or rescission described herein is conferred by Section 112 of the Securities Act (Prince Edward Island) (the “PEI Act”). The PEI Act provides, in relevant part, that if an offering memorandum (such as this presentation) contains a misrepresentation, as defined in the PEI Act, a purchaser who purchases a security offered by the offering memorandum during the period of distribution has, without regard to whether the purchaser relied on the misrepresentation, a right of action for damages. Such purchaser has a statutory right of action for damages against the issuer, the selling security holder on whose behalf the distribution is made, every director of the issuer at the date of the offering memorandum and every person who signed the offering memorandum. Alternatively, a purchaser who purchases a security offered by the offering memorandum during the period of distribution has a right of action for rescission against the issuer or the selling security holder on whose behalf the distribution is made, in which case the purchaser shall have no right of action for damages against the persons described above. No such action may be commenced to enforce the right of action for rescission or damages more than (a) 180 days after the day of the transaction that gave rise to the cause of action, in the case of an action for rescission, or (b) the earlier of (i) 180 days after the plaintiff first had knowledge of the facts giving rise to the cause of action, or (ii) three years after the day of the transaction giving rise to the cause of action, in any other case. These rights are in addition to, and without derogation from, any other rights or remedies available at law to a Prince Edward Island purchaser. The PEI Act provides a number of limitations and defences. The foregoing is a summary of the rights available to a Prince Edward Island purchaser. Prince Edward Island purchasers should refer to the complete text of the relevant statutory provisions.

Nova Scotia
The right of action for damages or rescission described herein is conferred by Section 138 of the Securities Act (Nova Scotia) (the “Nova Scotia Act”). The Nova Scotia Act provides, in relevant part, that in the event that an offering memorandum (such as this presentation), together with any amendment thereto, or any advertising or sales literature, as defined in the Nova Scotia Act, contains a misrepresentation, as defined in the Nova Scotia Act, the purchaser to whom the offering memorandum has been delivered and who purchases a security referred to therein will be deemed to have relied upon such misrepresentation if it was a misrepresentation at the time of purchase and has, subject to certain limitations and defences, a statutory right of action for damages against the issuer or other seller and, subject to certain additional defences, every director of the issuer at the date of the offering memorandum and every person who signed the offering memorandum or, alternatively, while still the owner of the securities purchased by the purchaser, may elect instead to exercise a statutory right of rescission against the issuer or other seller, in which case the purchaser shall have no right of action for damages against the issuer or other seller, directors of the issuer or any other person who has signed the offering memorandum, provided that certain criteria are met. These rights are in addition to, and without derogation from, any other rights or remedies available at law to a Nova Scotia purchaser. The Nova Scotia Act provides a number of limitations and defences in respect of such rights. The foregoing is a summary of the rights available to a Nova Scotia purchaser. Nova Scotia purchasers should refer to the complete text of the relevant statutory provisions.

Newfoundland and Labrador
The right of action for damages or rescission described herein is conferred by Section 130.1 of the Securities Act (Newfoundland and Labrador) (the “Newfoundland Act”). The Newfoundland Act provides, in relevant part, that where an offering memorandum (such as this presentation) contains a misrepresentation, as defined in the Newfoundland Act, a purchaser who purchases securities offered by the offering memorandum during the period of distribution has, without regard to whether the purchaser relied upon the misrepresentation, a statutory right of action (a) for damages against (i) the issuer, (ii) every director of the issuer at the date of the offering memorandum, and (iii) every person or company who signed the offering memorandum and (b) for rescission against the issuer. These rights are in addition to, and without derogation from, any other rights or remedies available at law to a Newfoundland and Labrador purchaser. The Newfoundland Act provides a number of limitations and defences in respect of such rights. The foregoing is a summary of the rights available to a Newfoundland and Labrador purchaser. Newfoundland and Labrador purchasers should refer to the complete text of the relevant statutory provisions.